US FDA (Food and Drug Administration) cleared Prevu, is a simple, non-invasive, inexpensive test used for cardiovascular risk assessment and has also received regulatory clearance for sale in Canada and Europe.

Miraculins president and CEO Christopher Moreau said that with the completion of the acquisition they can now begin to focus on implementing their plan to launch the Prevu skin cholesterol test and join the fight against cardiovascular disease, the leading cause of death worldwide.

“Miraculins looks forward to creating value for our shareholders as we work to realize our vision for this product,” Moreau said.